Lung cancer is the leading cause of cancer deaths in Pennsylvania and across the U.S., but the American Lung Association’s 2024 State of Lung Cancer report reveals some positive news for the Keystone State.
Nationally, the lung cancer survival rate has improved 26% in the last five years and 27% in Pennsylvania, which ranked 12th in the nation for survival.
The rate of early diagnosis in Pennsylvania has improved by 11% over the past five years, ranking 16th in the nation. Also, the rate of new lung cancer cases in Pennsylvania has declined by 16% over the past five years, ranking 32nd in the nation.
However, the report also reveals Pennsylvania has more smokers per capita than 31 other states — nearly 15% of Pennsylvanians smoke compared to about 13% nationally — and that state residents have a higher chance than average to be exposed to radon gas.
According to the U.S. Environmental Protection Agency, radon is a radioactive gas that forms naturally when uranium, thorium, or radium, which are radioactive metals, break down in rocks, soil and groundwater. People can be exposed to radon primarily from breathing radon in air that comes through cracks and gaps in buildings and homes.
Colorless and odorless, radon can cause lung cancer. Testing is the only way to know one’s level of exposure, according to the EPA.
Read More
The Lung Association report revealed that nearly 40% of radon tests in Pennsylvania indicate the presence of radon, higher than the national average.
Unfortunately, the report also found that Asian or Pacific Islander individuals in Pennsylvania are least likely to be diagnosed early (20% less likely). Additionally, Black Pennsylvanians are 14% more likely to be diagnosed with lung cancer and 8% less likely to receive surgery as the first course of treatment than their white counterparts.
The report suggests ways the state can improve lung cancer survival rates, including: increasing access to screening and biomarker testing, and implementing policies to require insurance coverage of comprehensive biomarker testing.
New this year, the report examined health insurance coverage requirements of comprehensive biomarker testing across the country.
Lung cancer biomarker testing — sometimes referred to as tumor, molecular, genomic or genetic testing — looks for changes in the tumor's DNA. The results of the test may show biomarkers that can help determine what treatment options would be best for an individual patient.
Insurance coverage of biomarker testing is important for removing a cost barrier to people with lung cancer, but coverage for biomarker testing is only required in some states, according to the report, which found that Pennsylvania does require insurance coverage of comprehensive biomarker testing.
“Lung cancer is a devastating disease and impacts far too many families in Pennsylvania. To address the burden of lung cancer and to help improve the lives of people it impacts, we must continue to evaluate the greatest needs. This report helps us prioritize which areas to focus on to truly make an impact,” said Elizabeth Hensil, the association’s advocacy director for Pennsylvania and West Virginia. “This year’s ‘State of Lung Cancer’ report shows that Pennsylvania must focus on lung health inequities, adult smoking cessation and radon testing and mitigation. Together, we can make a difference.”






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.